

Maartje Jacobs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5356125/publications.pdf>

Version: 2024-02-01

9
papers

131
citations

1478505

6
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

433
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening for Atrial Fibrillation in Sub-Saharan Africa: A Health Economic Evaluation to Assess the Feasibility in Nigeria. <i>Global Heart</i> , 2021, 16, 80.	2.3	2
2	Incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit. <i>Open Heart</i> , 2020, 7, e001226.	2.3	8
3	Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions. <i>Netherlands Heart Journal</i> , 2019, 27, 371-377.	0.8	18
4	Atrial Fibrillation in Africa – An Under-Reported and Unrecognized Risk Factor for Stroke: A Systematic Review. <i>Global Heart</i> , 2019, 14, 269.	2.3	12
5	Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. <i>Europace</i> , 2018, 20, euw285.	1.7	63
6	Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. <i>Current Medical Research and Opinion</i> , 2018, 34, 1839-1847.	1.9	13
7	The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands. <i>Journal of Medical Economics</i> , 2018, 21, 38-46.	2.1	3
8	Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. <i>European Journal of Health Economics</i> , 2018, 19, 957-965.	2.8	9
9	Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands. <i>Journal of Medical Economics</i> , 2017, 20, 1231-1236.	2.1	3